New HIV drug to become leading treatment by 2016.
Newly approved in the US, ViiV Healthcare’s Tivicay is set to become the world’s leading integrase inhibitor within the next three years, worth 12.6% of the market by 2022
The antiretroviral drug Tivicay, will become the leading integrase inhibitor for the treatment of HIV by 2016, according to independent analyst firm Datamonitor Healthcare. It is expected to generate annual sales of up to $2.1bn by 2022 in the US, Japan and five major EU markets*, equating to 12.6% of the total combined value of these markets.
Tivicay, which was recently approved in the US, had better efficacy than the protease inhibitor Prezista in clinical trials, and comparable efficacy with current integrase inhibitor standard of care Isentress. It is predicted that the drug will have a huge impact on the market following EU approval.
Dr Joseph Hedden, analyst at Datamonitor Healthcare said: “Unlike a number of its competitors, Tivicay doesn’t require co-dosing with a boosting agent. It also has a very attractive resistance profile. In the next few years, we are expecting these attributes to propel the drug into first place in terms of integrase inhibitor sales.”
The combined sales value of HIV drugs in the seven major markets** is expected to increase by 40% in the next decade, rising from $11.9bn in 2013 to $16.8bn in 2022. It is forecast that the market will peak at $17.3bn in 2020 after a strong period of growth stimulated by new drug launches and the increasing prevalence of HIV.
Between the forecast dates, the global patient population for HIV is expected to increase slowly, from 1.23 million in 2013 to just under 1.4 million in 2022. Out of the five major EU markets*, the UK will remain largest by patient number over the next decade, with the patient population estimated to be 135 million by 2022. The projected annual growth rate for the UK is 6.2%, the fastest of all the major markets**.
Additional forecasts, opinion and research from Datamonitor Healthcare is available at www.datamonitorhealthcare.com
*5 major EU markets = France, Germany, Italy, Spain, UK
** 7 major markets = US, Japan and the 5 major EU markets.
Media Contact: Lucy Giles @ MC2 | 0161 236 1352 | LucyG@mcmc.co.uk
About Datamonitor Healthcare
Datamonitor Healthcare is a world-leading provider of premium business information, delivering research and analysis of all aspects of the healthcare sector.
Notes to editors
Whenever citing an analyst or quote, please remember to use ‘Datamonitor Healthcare’ rather than ‘Datamonitor’.
For descriptive purposes, Datamonitor Healthcare is a “leading research and consulting firm.”
Whenever possible, please hyperlink:
The Datamonitor Healthcare name to www.datamonitorhealthcare.com
Any reports used to the correct URL for that listing on our Report Store.
Please note that all supplied to the media, is owned exclusively by Datamonitor Healthcare, is governed by our terms and conditions, and therefore must be referenced.
Posted in Infectious Diseases.